Review Article
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease
Table 2
Selective-TLR antagonists in cardiovascular disease.
| Compound | Target | Indication | Drug class | Clinical phase | Company |
| OPN-305 | TLR2 | Inflammation, autoimmunity, I/R injury | Antibody | Preclinical | Opsona Therapeutics | Eritoran | TLR4 | Sepsis I/R injury (preclinical) | Synthetic lipopolysacharide | Phase III | Eisai Pharmaceuticals | TAK-242 | TLR4 | Sepsis, inflammation | Small-molecule inhibitor | Discontinued in phase III | Takeda | NI-0101 | TLR4 | Inflammation, autoimmunity, CVD, I/R injury, and so forth | Antibody | Preclinical | Novimmune | IMO-3100 | TLR7 and TLR9 | SLE, RA, MS, atherosclerosis | DNA-based compound | Preclinical | Idera Pharmaceuticals |
|
|
CVD: cardiovascular disease; MS: multiple sclerosis; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; I/R: ischaemia reperfusion.
|